Palifermin
- TRADE NAME: Kepivance (Amgen)
- INDICATIONS: Severe oral mucositis in cancer patients
- CLASS: Keratinocyte growth factor
- HALF-LIFE: 4.5 hours
CLINICALLY IMPORTANT, POTENTIALLY HAZARDOUS INTERACTIONS WITH:
PREGNANCY CATEGORY: C
Please login to see the rest of this drug profile
SKIN.
MUCOSAL.
CARDIOVASCULAR.
CENTRAL NERVOUS SYSTEM.
NEUROMUSCULAR/SKELETAL.
OTHER.
Page last updated 07/31/2023
Symbol key
Incidence
- <1%
- 1-5%
- 5-10%
- 10-15%
- 15-20%
- 20-30%
- >30%
Warnings in other populations
- Breast feeding
- Geriatric
- Pediatric